J. Rothenstein

1.3k total citations
25 papers, 530 citations indexed

About

J. Rothenstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. Rothenstein has authored 25 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in J. Rothenstein's work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Genomics and Diagnostics (8 papers). J. Rothenstein is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Genomics and Diagnostics (8 papers). J. Rothenstein collaborates with scholars based in Canada, United States and Spain. J. Rothenstein's co-authors include Nathalie Letarte, Barbara Melosky, Eric Clelland, Parneet Cheema, Chun Peng, Vera Hirsh, Natasha B. Leighl, David J. Stewart, Anthony Brade and Kim Papp and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. Rothenstein

25 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Rothenstein Canada 13 305 297 116 61 45 25 530
Matilde Pensabene Italy 16 194 0.6× 234 0.8× 184 1.6× 141 2.3× 66 1.5× 35 597
Alexander B. Sibley United States 12 80 0.3× 171 0.6× 124 1.1× 71 1.2× 57 1.3× 27 393
Amy Prawira Canada 11 147 0.5× 326 1.1× 172 1.5× 111 1.8× 22 0.5× 38 621
Joan Morote Spain 11 194 0.6× 114 0.4× 175 1.5× 65 1.1× 87 1.9× 22 489
Mariana Brandão Belgium 16 200 0.7× 468 1.6× 154 1.3× 181 3.0× 27 0.6× 65 721
Silvia P. Neciosup Peru 13 203 0.7× 409 1.4× 245 2.1× 233 3.8× 33 0.7× 46 720
Prateek Mendiratta United States 13 256 0.8× 240 0.8× 184 1.6× 118 1.9× 13 0.3× 37 584
Valentina Tuninetti Italy 12 100 0.3× 271 0.9× 186 1.6× 125 2.0× 23 0.5× 28 600
Claudia Arce-Salinas Mexico 11 80 0.3× 241 0.8× 138 1.2× 177 2.9× 27 0.6× 25 448
Arwa Ali Saudi Arabia 12 207 0.7× 304 1.0× 237 2.0× 209 3.4× 27 0.6× 34 620

Countries citing papers authored by J. Rothenstein

Since Specialization
Citations

This map shows the geographic impact of J. Rothenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Rothenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Rothenstein more than expected).

Fields of papers citing papers by J. Rothenstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Rothenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Rothenstein. The network helps show where J. Rothenstein may publish in the future.

Co-authorship network of co-authors of J. Rothenstein

This figure shows the co-authorship network connecting the top 25 collaborators of J. Rothenstein. A scholar is included among the top collaborators of J. Rothenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Rothenstein. J. Rothenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barnes, T., Janessa Laskin, Parneet Cheema, et al.. (2023). The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing—Patient’s Willingness-to-Pay: A Brief Report. JTO Clinical and Research Reports. 5(1). 100615–100615. 1 indexed citations
2.
Breadner, Daniel, Geoffrey Liu, J. Rothenstein, et al.. (2023). 1327P First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis). Annals of Oncology. 34. S766–S766. 2 indexed citations
3.
Fung, Andrea S., Donna M. Graham, Eric X. Chen, et al.. (2021). A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer. 157. 21–29. 9 indexed citations
4.
Reck, Martin, Thomas Wehler, Francesco Orlandi, et al.. (2020). Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 38(22). 2530–2542. 56 indexed citations
5.
Laurie, Scott A., Shantanu Banerji, Normand Blais, et al.. (2019). Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology. 26(1). 81–93. 35 indexed citations
6.
Cheema, Parneet, J. Rothenstein, Barbara Melosky, Anthony Brade, & Vera Hirsh. (2019). Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer. Current Oncology. 26(1). 37–42. 54 indexed citations
7.
Rothenstein, J., Alexander I. Spira, Vamsidhar Velcheti, et al.. (2018). P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab. Journal of Thoracic Oncology. 13(10). S495–S495. 3 indexed citations
8.
Graham, David L., Penelope A. Bradbury, Martina Trinkaus, et al.. (2018). P1.01-54 A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S481–S482. 2 indexed citations
9.
Juergens, Rosalyn A., Caroline Mariano, Jacques Jolivet, et al.. (2018). Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology. 25(6). 384–392. 46 indexed citations
10.
Rothenstein, J., et al.. (2018). ALK Inhibitors, Resistance Development, Clinical Trials. Current Oncology. 25(11). 59–67. 35 indexed citations
11.
Reck, Martin, Tom C. Karagiannis, Thomas Wehler, et al.. (2018). Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).. Journal of Clinical Oncology. 36(15_suppl). 9047–9047. 10 indexed citations
12.
Juergens, Rosalyn A., Quincy S. Chu, J. Rothenstein, et al.. (2017). P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients. Journal of Thoracic Oncology. 12(11). S2426–S2427. 12 indexed citations
13.
Kayaniyil, Sheena, Joanna Y. Wilson, Paul Wheatley‐Price, et al.. (2016). Treatment Patterns and Survival in Patients with ALK-Positive Non-small-Cell Lung Cancer: A Canadian Retrospective Study. Current Oncology. 23(6). 589–597. 15 indexed citations
14.
Melosky, Barbara, Natasha B. Leighl, J. Rothenstein, et al.. (2015). Management of egfr tki—Induced Dermatologic Adverse Events. Current Oncology. 22(2). 123–132. 54 indexed citations
15.
Rothenstein, J. & Nathalie Letarte. (2014). Managing Treatment–Related Adverse Events Associated with Alk Inhibitors. Current Oncology. 21(1). 19–26. 49 indexed citations
16.
Rothenstein, J., George Tomlinson, Ian F. Tannock, & Allan S. Detsky. (2011). Company Stock Prices Before and After Public Announcements Related to Oncology Drugs. JNCI Journal of the National Cancer Institute. 103(20). 1507–1512. 24 indexed citations
17.
Rothenstein, J., et al.. (2004). Community paediatricians’ counseling patterns and knowledge of recommendations relating to child restraint use in motor vehicles. Injury Prevention. 10(2). 103–106. 12 indexed citations
18.
19.
Donovan, Jeffrey, J. Rothenstein, & Joyce M. Slingerland. (2002). Non-malignant and Tumor-derived Cells Differ in Their Requirement for p27Kip1 in Transforming Growth Factor-β-mediated G1 Arrest. Journal of Biological Chemistry. 277(44). 41686–41692. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matilde Pensabene Breakdown of academic impact, for papers by Alexander B. Sibley Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Joan Morote Breakdown of academic impact, for papers by Mariana Brandão Breakdown of academic impact, for papers by Silvia P. Neciosup Breakdown of academic impact, for papers by Prateek Mendiratta Breakdown of academic impact, for papers by Valentina Tuninetti Breakdown of academic impact, for papers by Claudia Arce-Salinas Breakdown of academic impact, for papers by Arwa Ali
Rankless by CCL
2026